Literature DB >> 17080767

Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.

Satoshi Morita1, Junichi Sakamoto.   

Abstract

Randomized phase II selection trials seek to provide unbiased comparisons for the selection of the most promising treatment arm for evaluation in a future phase III trial. In this paper, we present an application of an adaptive design to a randomized phase II selection trial comparing three experimental treatments with a control arm in patients with advanced gastric cancer. The trial design continuously monitors multiple patient outcomes to protect future patients from treatments with unacceptably high toxicity and/or unacceptably low efficacy. We use a Bayesian approach to monitor the trial and carry out simulations to investigate operating characteristics of the trial design. The simulation study also evaluates the sensitivity of the design to the prior distribution by considering two alternative priors.

Entities:  

Mesh:

Year:  2006        PMID: 17080767     DOI: 10.1002/pst.220

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  3 in total

Review 1.  Clinical research methodology I: introduction to randomized trials.

Authors:  Lillian S Kao; Jon E Tyson; Martin L Blakely; Kevin P Lally
Journal:  J Am Coll Surg       Date:  2008-02       Impact factor: 6.113

2.  Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.

Authors:  Rebecca A Miksad; Mithat Gönen; Thomas J Lynch; Thomas G Roberts
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

3.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.